PD-L1 inhibitors block only PD-L1, preserving PD-L2 binding to PD-1 (PD-L2 is expressed in some normal tissues), which may theoretically reduce some side effects, but the clinical differences are not yet significant.
← all excerpts
Comparing efficacy of neoadjuvant therapy of triple-negative breast cancer: A Bayesian network meta-regression analysis.
1
—
—